
J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma
Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical giant has expanded in this space with additional drugs …